Overview
InSphero offers scalable 3D in vitro models for non-animal drug testing in pharma and life sciences, including ARCTis™ cryopreserved human-derived 3D tumor models and 3D InSight™ Human Liver Microtissues. These solutions support liver disease research (MASH/NAFLD), toxicology, oncology, immunology, and safety assessment with high physiological relevance, reproducibility, and automation compatibility. They enable reliable prediction of human responses, reducing late-stage failures and accelerating drug discovery.
Frequently asked questions
- What 3D in vitro models does InSphero offer for pharma R&D?
- InSphero provides ARCTis™ cryopreserved 3D tumor models, 3D InSight™ Human Liver Microtissues for liver disease and toxicology, and models for oncology, immunology, diabetes, and MASH/NAFLD, all with high scalability and physiological relevance.
- What are the key capabilities and applications of InSphero's platforms?
- Platforms offer high reproducibility, short turnaround times, multiplexing for imaging and readouts, compatibility with small molecules, biologics, and siRNAs, and applications in toxicology, safety testing, efficacy assessment, and tumor microenvironment studies.
- Does InSphero comply with regulatory standards for drug testing?
- InSphero's solutions include ISO quality-controlled 3D human tissue models used by major pharmaceutical companies worldwide for preclinical drug safety and efficacy testing.
- What geographies does InSphero serve and are they scalable?
- InSphero serves global pharmaceutical and biotech clients with automation-compatible, scalable 3D technology like Akura™ Microplates, enabling industrial-grade assays.